Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
The antiserum was produced against synthesized phosphopeptide derived from humanFKHR around the phosphorylation site of serine 319 (T-S-SP-N-A).
Buffer
phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Clone Name
Isotype
Species Reactivity
Human, Mouse, Rat
Concentration
1ug/ul
Purification
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography usingepitope-specific phosphopeptide. The antibody against non-phosphopeptide was removedby chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site. (Protein A or G Sepharose)
Guaranteed Application *
WB, IHC
Suggested Dilutions
WB: 1:500~1:1000, IHC: 1:50~1:100
Background
Related Pathway
Adipogenesis
EGFR1 Signaling Pathway
TGF Beta Signaling Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of extracts from 293 cells (10% serum-treated, 15min) and HeLa cells (EGF-treated, 200ng/ml, 15min), using FKHR antibody (Lanes 1, 2 and 3) and FKHR (phospho-Ser319) antibody (Lanes 4 and 5).
